ArticleFrontiers in oncology2026
More is not always better: higher lymph node yield is not associated with improved survival in stage I-III colorectal cancer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is among the most prevalent malignancies worldwide and remains the second leading cause of cancer-related death. Curative treatment approaches rely on R0 resection with adequate regional lymphadenectomy. Current international guidelines recommend a lymph node yield (LNY) of at least 12 lymph nodes to ensure accurate pathological staging and to guide decisions regarding adjuvant therapy. However, it remains controversial whether this historically established threshold is sufficient to optimize oncological outcomes. The aim of this study was to evaluate the association between operative LNY and clinicopathological characteristics, disease-free survival (DFS), and overall survival (OS) in patients undergoing curative resection for CRC. Methods: This retrospective study included 333 patients who underwent colorectal cancer resection at a high-volume center in Germany between 2016 and 2023. Only patients with Union for International Cancer Control (UICC) stage I-III disease who underwent curative-intent R0 resection were included. Patients were stratified into two groups according to LNY: <20 versus ≥20 retrieved lymph nodes. Results: LNY of ≥20 was associated with distinct tumor- and treatment-related characteristics, including advanced local tumor stage, microsatellite instability (MSI), colon cancer, right hemicolectomy, and absence of neoadjuvant treatment. No significant differences were observed between the groups regarding nodal stage, number of positive lymph nodes, lymphatic invasion, surgical approach, urgency of surgery, intraoperative blood loss, major postoperative morbidity, anastomotic leakage, chyle leak, reoperation or length of hospital stay. Higher LNY was not independently associated with improved OS or DFS in the overall cohort. Subgroup analyses stratified by UICC stage showed no significant association between LNY ≥20 on OS or DFS in stage I, II, or III disease. In procedure-specific analyses, LNY ≥20 was associated with improved OS after anterior rectal resection. Conclusions: Overall, these findings suggest that higher LNY is not a general prognostic determinant of oncological outcomes, but may have procedure-specific prognostic relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.